Clinical Trials

Inclusion Criteria:

- Participant must be ≥ 18 to ≤ 89 years of age, at the time of signing the informed consent

- Confirmed diagnosis of MOG-AD consistent with published diagnostic criteria for MOG-AD

- Participant has history of relapsing MOG-AD with at least 1 documented relapse over the last 12 months and a documented positive serum MOG Ab test using a cell-based
assay (CBA) within 6 months prior to randomization

- Participant must be clinically stable at the time of the Screening Visit and during the Screening Period

Exclusion Criteria:

- Participant has been diagnosed with a neurological autoimmune disease (including multiple sclerosis (MS) and aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD)), or a systemic autoimmune disease that in the opinion of the investigator can interfere with the safety of the participant

- Participant has a clinically important active infection (including unresolved or not adequately treated infection) as assessed by the investigator

- Participant has a current or medical history of primary immunodeficiency

- Participant tests positive for aquaporin-4 antibodies at Screening

- Participant has a serum total IgG level ≤ 5.5g/L

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/18/23. Questions regarding updates should be directed to the study team contact.